Empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells

SGLT-2 inhibitors, such as empagliflozin, have been shown to reduce the occurrence of cardiovascular events and delay the progression of atherosclerosis. However, its role in atherosclerotic calcification remains unclear. In this research, ApoE−/− mice were fed with western diet and empagliflozin wa...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Junping Li, Changping Li, Zhaoqi Huang, Chunling Huang, Juanzhang Liu, Tao Wu, Shuwan Xu, Peibiao Mai, Dengfeng Geng, Shuxian Zhou, Kun Zhang, Zhaoyu Liu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-11-01
coleção:	Frontiers in Pharmacology
Assuntos:	atherosclerosis arterial calcification empagliflozin osteogenic differentiation vascular smooth muscle cell
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1295463/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!